The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons

被引:11
|
作者
Hall, Heather [1 ]
Cote, Joanne [2 ]
McBean, Althea [2 ]
Purden, Margaret [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Sch Nursing, Ctr Nursing Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada
来源
HEART & LUNG | 2012年 / 41卷 / 01期
关键词
Epoprostenol; Pulmonary arterial hypertension; Qualitative; Resilience; Support persons; Technology; QUALITY-OF-LIFE; RESILIENCE; THERAPY; HOME; PROSTACYCLIN;
D O I
10.1016/j.hrtlng.2011.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol. METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included. RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role. CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH. Cite this article: Hall, H., Cote, J., McBean, A., & Purden, M. (2012, JANUARY/FEBRUARY). The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart & Lung, 41(1), 35-43. doi:10.1016/j.hrtlng.2011.05.007.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [1] The experiences of patients with Pulmonary Arterial Hypertension (PAH) receiving continuous intravenous infusion of epoprostenol (Flolan™), and their support persons
    Hall, Heather
    Cote, Joanne
    McBean, Althea
    CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 : 323C - 323C
  • [2] Veletri® and Flolan® (Epoprostenol Sodium) in the Treatment of Pulmonary Arterial Hypertension
    Chin, K. M.
    Badesch, D. B.
    Robbins, I. M.
    Tapson, V. F.
    Palevsky, H.
    Kim, N. H.
    Kawut, S. M.
    Frost, A.
    Benton, W. W.
    Lemarie, J. C.
    Bodin, F.
    Rubin, L. J.
    McLaughlin, V. V.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S28 - S28
  • [3] Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
    Kimura, Mai
    Tamura, Yuichi
    Takei, Makoto
    Yamamoto, Tsunehisa
    Ono, Tomohiko
    Kuwana, Masataka
    Fukuda, Keiichi
    Satoh, Toru
    PLOS ONE, 2015, 10 (04):
  • [4] A comparison of rapid and slow initiation of intravenous epoprostenol infusion in patients with advanced pulmonary arterial hypertension
    Kimura, M.
    Tamura, Y.
    Yamamoto, T.
    Takei, M.
    Kataoka, M.
    Kawakami, T.
    Kuwana, M.
    Sano, M.
    Satoh, T.
    Fukuda, K.
    EUROPEAN HEART JOURNAL, 2014, 35 : 77 - 78
  • [5] Rapid Initiation of Intravenous Epoprostenol Infusion is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
    Kimura, Mai
    Tamura, Yuichi
    Takei, Makoto
    Yamamoto, Tsunehisa
    Ono, Tomohiko
    Kawakami, Takashi
    Kataoka, Masaharu
    Kuwana, Masataka
    Satoh, Toru
    Fukuda, Keiichi
    JOURNAL OF CARDIAC FAILURE, 2014, 20 (10) : S163 - S163
  • [6] Urticaria induced by continuous intravenous epoprostenol treatment in a patient with pulmonary arterial hypertension
    Sawada, Tomoya
    Kuwai, Takumi
    Nakajima, Saeko
    Chen-Yoshikawa, Toyofumi Fengshi
    Nomura, Takashi
    Date, Hiroshi
    Kabashima, Kenji
    JOURNAL OF DERMATOLOGY, 2024, 51 (12): : e431 - e432
  • [7] Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
    Kuo, PC
    Johnson, LB
    Plotkin, JS
    Howell, CD
    Bartlett, ST
    Rubin, LJ
    TRANSPLANTATION, 1997, 63 (04) : 604 - 606
  • [8] Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol
    Kuhn, KP
    Byrne, DW
    Arbogast, PG
    Doyle, TP
    Loyd, JE
    Robbins, IM
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (04) : 580 - 586
  • [9] Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol
    Demerouti, Eftychia
    Karyofyllis, Panagiotis
    Manginas, Athanassios
    Anthi, Anastasia
    Karatasakis, George
    Athanassopoulos, George
    Voudris, Vassilios
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (02) : 99 - 105
  • [10] Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol
    Eftychia Demerouti
    Panagiotis Karyofyllis
    Athanassios Manginas
    Anastasia Anthi
    George Karatasakis
    George Athanassopoulos
    Vassilios Voudris
    American Journal of Cardiovascular Drugs, 2019, 19 : 99 - 105